1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [f086b6d3-e602-47b6-8343-daca0263c6f3] => Array
        (
            [runtime-id] => f086b6d3-e602-47b6-8343-daca0263c6f3
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [c440bbf7-d37e-4bb9-a370-69a3c8d43e37] => Array
                        (
                            [runtime-id] => c440bbf7-d37e-4bb9-a370-69a3c8d43e37
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;c485e795f17b2e8a77c2017f9a9d047928ac8145
                )

        )

)
1naresh2naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

    [f086b6d3-e602-47b6-8343-daca0263c6f3] => Array
        (
            [runtime-id] => f086b6d3-e602-47b6-8343-daca0263c6f3
            [type] => toll-free-key
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [c440bbf7-d37e-4bb9-a370-69a3c8d43e37] => Array
                        (
                            [runtime-id] => c440bbf7-d37e-4bb9-a370-69a3c8d43e37
                            [type] => toll-free-key
                        )

                )

            [credentials] => Array
                (
                    [method] => toll-free-key
                    [value] => tf_ipsecsha;c485e795f17b2e8a77c2017f9a9d047928ac8145
                )

        )

)


Table 1: 
Patient demographics and clinicopathologic informationa
TE (n = 17)Tumor (n = 30)Total (n = 47)
Age (yr)
Mean (SD)56 (10)55 (13)55 (12)
Range38-7720-8020-80
Sex
Male11 (65%)18 (60%)29 (62%)
Female6 (35%)12 (40%)18 (38%)
Interval time between end or radiation therapy and surgery (mo)
Median (range)11.4 (0.6-60.4)10.7 (1.3-101.5)10.9 (0.6-101.5)
Bevacizumab at time of surgeryb2 (12%)3 (10%)5 (11%)
Surgical procedure
Biopsy3 (18%)4 (13%)7 (15%)
>90% resection3 (18%)9 (30%)12 (25%)
Gross total resection11 (64%)17 (57%)28 (60%)
HGG histopathology
Anaplastic astrocytoma, WHO grade III2 (12%)02 (4%)
Glioblastoma, WHO grade IV15 (88%)29 (97%)44 (94%)
Gliosarcoma, WHO grade IV01 (3%)1 (2%)
HGG molecular features
IDH wild type11 (65%)11 (37%)22 (47%)
IDH mutant02 (7%)2 (4%)
Unknown IDH status6 (35%)17 (56%)23 (49%)
MGMT-unmethylated6 (35%)15 (50%)21 (45%)
MGMT-methylated6 (35%)8 (27%)14 (30%)
Unknown MGMT status5 (30%)7 (23%)12 (25%)
  • Note:—IDH indicates isocitrate dehydrogenase; MGMT, O-6-methylguanine-DNA methyltransferase; WHO, World Health Organization.
  • ↵a Percentage values in parentheses for sex, bevacizumab at time of the operation, surgical procedure, HGG histopathology, and HGG molecular features are percentages relative to the number of patients in each column.
  • ↵b Patient received a dose of bevacizumab within 1 month of the surgical procedure for suspected recurrence.